ABVC BioPharma IncABVC
Price$1.06

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $296K0.0% YoYTTM through 30 Sep 2025
Net Income -$7.1MTTM through 30 Jun 2026
Free Cash Flow -$2.7MTTM through 30 Jun 2026

Margins

Current
Operating Margin-2,201.1%
Net Margin-2,400.9%

Returns

-87.8%ROE
-43.7%ROA

Balance Sheet Health

Debt / Equity0.21x
Current Ratio0.12x
Net Debt$685.5K
Cash & Equivalents$31.9K

Quality Metrics

Altman Z-Score-4.53
Piotroski F-Score3 / 9
FCF Margin-909.1%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'15'24'25
FY2025: $296K
Diluted EPS-$0.29TTM
'18'20'21'22'23'24'25
FY2025: $-0.39

Dividend

No dividend

Capital Allocation

R&D Spend$114.8K

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.